Centerline Biomedical appears in FDA 510(k) records as the applicant for the Intra-Operative Positioning System (IOPS) and IOPS Visionary System, cleared under K263016 with a substantially equivalent decision dated October 1, 2026. The filing lists the device under product code DQK, regulation number 870.1425, Class II, with a cardiovascular advisory committee. The company's published documentation describes IOPS as electromagnetic tracking that shows the position and orientation of sensor-equipped devices inside a patient-specific 3D vascular map, used alongside fluoroscopy rather than in place of it. [1][2][5]
The K263016 filing and its scope
The FDA record for K263016 names Centerline Biomedical as applicant, with a decision code of SESE and a decision description of substantially equivalent, received August 28, 2026 and decided October 1, 2026. The clearance type is recorded as Special, the third-party flag as N, and a summary is noted as available. The device is listed as the Intra-Operative Positioning System (IOPS) and IOPS Visionary System under product code DQK, regulation 870.1425, device class 2, with the cardiovascular advisory committee. [1]
A separate FDA substantial equivalence determination for K254089, dated February 17, 2026, addresses the IOPS Visionary device under regulation 21 CFR 870.1425, Class II, with product codes DQK, DQY and DQX. That document describes the system as indicated for endovascular interventions in the peripheral, aortic and aortic side branch vasculature, as an adjunct to fluoroscopy, and states that the IOPS does not make a diagnosis. It identifies the predicate as the Intra-Operative Positioning System, K243842, and describes software that builds a vascular map from a preoperative CT scan to show sensorized catheter and guidewire locations in real time. [4]
Documented components and software features
Centerline Biomedical's IOPS software page lists building 3D, multi-color models of patient anatomy from existing CT scans, showing up to four views of the anatomy concurrently, capturing 3D intraoperative image updates with Spintegration, displaying position and orientation of IOPS catheters, guidewires and implanted devices, and working with all CBCT imaging systems. The same page describes rotating, magnifying and annotating procedural targets within the 3D model in real time. [6]
The company's technology page describes IOPS as a 3D navigation and visualization technology with interactive navigation and real-time positioning, a portable system, and reduced radiation exposure relative to X-ray fluoroscopy, which it characterizes as low-quality 2D image guidance relying on radiation and contrast dye. The page presents a physician quotation attributed to Rishi Puri, MD, of Cleveland Clinic. Company-published feature descriptions remain the manufacturer's own characterizations. [3]
Positioning as an adjunct to fluoroscopy
Centerline Biomedical's published technology material states that IOPS uses electromagnetic tracking to determine the position and orientation of sensor-equipped devices and displays them in real time within a patient-specific 3D vascular map, that the tracking technology does not emit ionizing radiation, and that IOPS is used as an adjunct to fluoroscopy. The FDA determination for K254089 likewise frames the system as an adjunct to fluoroscopy and states that it does not make a diagnosis. [4][9]
The company's indications page presents the IOPS intended use as evaluation of vascular anatomy as captured using patient imaging, without adding diagnostic claims. The IOPS Visionary page describes a tableside controller and real-time tracking of IOPS-enabled devices through the 3D vascular map, and labels its callouts as provisional client-review copy. [7][8]
What the record does not establish
The linked collection contains one 510(k) record, K263016, with a single SESE decision; this is an as-of snapshot of the filings provided, not a measure of total portfolio, sales or safety performance. The FDA filing address in Warrensville Heights, Ohio, is a correspondence address on the application and is not treated here as a verified headquarters. No parent, brand owner, customer list, certification or commercial availability is established by these documents. [1][2]


